Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2012 Mar 13;106(6):1214-23. doi: 10.1038/bjc.2012.59. Epub 2012 Feb 28.

Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.

Author information

1
Department of Vascular Biology, Graduate School of Dental Medicine, N13 W7, University of Hokkaido, Sapporo, Hokkaido 060-8586, Japan.

Abstract

BACKGROUND:

We isolated tumour endothelial cells (TECs), demonstrated their abnormalities, compared gene expression profiles of TECs and normal endothelial cells (NECs) by microarray analysis and identified several genes upregulated in TECs. We focused on the gene encoding biglycan, a small leucine-rich repeat proteoglycan. No report is available on biglycan expression or function in TECs.

METHODS:

The NEC and TEC were isolated. We investigated the biglycan expression and function in TECs. Western blotting analysis of biglycan was performed on sera from cancer patients.

RESULTS:

Biglycan expression levels were higher in TECs than in NECs. Biglycan knockdown inhibited cell migration and caused morphological changes in TECs. Furthermore, immunostaining revealed strong biglycan expression in vivo in human tumour vessels, as in mouse TECs. Biglycan was detected in the sera of cancer patients but was hardly detected in those of healthy volunteers.

CONCLUSION:

These findings suggested that biglycan is a novel TEC marker and a target for anti-angiogenic therapy.

PMID:
22374465
PMCID:
PMC3304426
DOI:
10.1038/bjc.2012.59
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center